ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is a single institution phase I/II study using an ADAM17 inhibitor (INCB7839) with
rituximab as consolidation therapy after an autologous hematopoietic cell transplant (HCT)
for patients with diffuse large B cell lymphoma (DLBCL). The study consists of two phases.
The dose finding phase is a modified version of a phase I trial and the extended phase is a
modified version of a phase II trial.